Inhibition of glucosylceramide accumulation results in effective blockade of polycystic kidney disease in mouse models

Nature Medicine

Volumn 16, Issue 7, 2010, Pages 788-792

  Natoli, Thomas A ^a   Smith, Laurie A ^a   Rogers, Kelly A ^a   Wang, Bing ^a   Komarnitsky, Svetlana ^a   Budman, Yeva ^a   Belenky, Alexei ^a   Bukanov, Nikolay O ^a   Dackowski, William R ^a   Husson, Hervé ^a   Russo, Ryan J ^a   Shayman, James A ^b   Ledbetter, Steven R ^a   Leonard, John P ^a   Ibraghimov Beskrovnaya, Oxana ^a  

^a GENZYME CORPORATION   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERAMIDE GLUCOSYLTRANSFERASE INHIBITOR; GANGLIOSIDE GM3; GENZ 123346; GLUCOSYLCERAMIDE; GLYCOSPHINGOLIPID; MAMMALIAN TARGET OF RAPAMYCIN; POLYCYSTIN 1; PROTEIN JCK; PROTEIN KINASE B; PROTEIN PCY; TAMOXIFEN; TRANSIENT RECEPTOR POTENTIAL CHANNEL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CYCLE REGULATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; ENZYME INHIBITION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; KIDNEY; KIDNEY PARENCHYMA; KIDNEY POLYCYSTIC DISEASE; LOW DRUG DOSE; MOLECULAR GENETICS; MOUSE; NEPHRONOPHTHISIS; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; CELL CYCLE; DIOXANES; DISEASE MODELS, ANIMAL; G(M3) GANGLIOSIDE; GLUCOSYLCERAMIDES; GLUCOSYLTRANSFERASES; GLYCOSPHINGOLIPIDS; HUMANS; MICE; MICE, KNOCKOUT; POLYCYSTIC KIDNEY DISEASES; PYRROLIDINES; RATS;

MAMMALIA; MUS;

EID: 77954488392     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2171     Document Type: Article

References (40)

1. Torres, V.E. & Harris, P.C. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int. 76, 149-168 (2009).
2. Bukanov, N.O., Smith, L.A., Klinger, K.W., Ledbetter, S.R. & Ibraghimov-Beskrovnaya, O. Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. Nature 444, 949-952 (2006).
3. Tao, Y., Kim, J., Schrier, R.W. & Edelstein, C.L. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J. Am. Soc. Nephrol. 16, 46-51 (2005).
4. Leuenroth, S.J., Bencivenga, N., Chahboune, H., Hyder, F. & Crews, C.M. Triptolide reduces cyst formation in a neonatal to adult transition Pkd1 model of ADPKD. Nephrol. Dial Transplant. published online, doi:10.1093/ndt/ gfp777 (4 February 2010).
5. Gattone, V.H. II, Wang, X., Harris, P.C. & Torres, V.E. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat. Med. 9, 1323-1326 (2003).
6. Ruggenenti, P. et al. Safety and effcacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int. 68, 206-216 (2005).
7. Wahl, P.R. et al. Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol. Dial. Transplant. 21, 598-604 (2006).
8. Shillingford, J.M., Piontek, K.B., Germino, G.G. & Weimbs, T. Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. J. Am. Soc. Nephrol. 21, 489-497 (2010).
9. Bieberich, E. Integration of glycosphingolipid metabolism and cell-fate decisions in cancer and stem cells: review and hypothesis. Glycoconj. J. 21, 315-327 (2004).
10. Gabow, P.A. Autosomal dominant polycystic kidney disease. N. Engl. J. Med. 329, 332-342 (1993).
11. Igarashi, P. & Somlo, S. Genetics and pathogenesis of polycystic kidney disease. J. Am. Soc. Nephrol. 13, 2384-2398 (2002).
12. Hildebrandt, F., Attanasio, M. & Otto, E. Nephronophthisis: disease mechanisms of a ciliopathy. J. Am. Soc. Nephrol. 20, 23-35 (2009).
13. Quarmby, L.M. & Parker, J.D. Cilia and the cell cycle? J. Cell Biol. 169, 707-710 (2005).
14. Simons, M. et al. Inversin, the gene product mutated in nephronophthisis type II, functions as a molecular switch between Wnt signaling pathways. Nat. Genet. 37, 537-543 (2005).
15. Yamaguchi, T. et al. Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J. Biol. Chem. 279, 40419-40430 (2004).
16. Wahl, P.R. et al. Mitotic activation of Akt signalling pathway in Han:SPRD rats with polycystic kidney disease. Nephrology (Carlton) 12, 357-363 (2007).
17. Masoumi, A., Reed-Gitomer, B., Kelleher, C. & Schrier, R.W. Potential pharmacological interventions in polycystic kidney disease. Drugs 67, 2495-2510 (2007).
18. Lahiri, S. & Futerman, A.H. The metabolism and function of sphingolipids and glycosphingolipids. Cell. Mol. Life Sci. 64, 2270-2284 (2007).
19. Chatterjee, S., Shi, W.Y., Wilson, P. & Mazumdar, A. Role of lactosylceramide and MAP kinase in the proliferation of proximal tubular cells in human polycystic kidney disease. J. Lipid Res. 37, 1334-1344 (1996).
20. Rani, C.S. et al. Cell cycle arrest induced by an inhibitor of glucosylceramide synthase. Correlation with cyclin-dependent kinases. J. Biol. Chem. 270, 2859-2867 (1995).
21. Cuvillier, O. et al. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature 381, 800-803 (1996).
22. Hong, S., Huo, H., Xu, J. & Liao, K. Insulin-like growth factor-1 receptor signaling in 3T3-L1 adipocyte differentiation requires lipid rafts but not caveolae. Cell Death Differ. 11, 714-723 (2004). (Pubitemid 39023118)
23. Yamashita, T. et al. Enhanced insulin sensitivity in mice lacking ganglioside GM3. Proc. Natl. Acad. Sci. USA 100, 3445-3449 (2003).
24. Rebbaa, A., Hurh, J., Yamamoto, H., Kersey, D.S. & Bremer, E.G. Ganglioside GM3 inhibition of EGF receptor mediated signal transduction. Glycobiology 6, 399-406 (1996).
25. Tagami, S. et al. Ganglioside GM3 participates in the pathological conditions of insulin resistance. J. Biol. Chem. 277, 3085-3092 (2002).
26. Deshmukh, G.D., Radin, N.S., Gattone, V.H. II & Shayman, J.A. Abnormalities of glycosphingolipid, sulfatide and ceramide in the polycystic (cpk/cpk) mouse. J. Lipid Res. 35, 1611-1618 (1994).
27. Janich, P. & Corbeil, D. GM1 and GM3 gangliosides highlight distinct lipid microdomains within the apical domain of epithelial cells. FEBS Lett. 581, 1783-1787 (2007).
28. Lee, L., Abe, A. & Shayman, J.A. Improved inhibitors of glucosylceramide synthase. J. Biol. Chem. 274, 14662-14669 (1999).
29. Abe, A. et al. Improved inhibitors of glucosylceramide synthase. J. Biochem. 111, 191-196 (1992).
30. Zhao, H. et al. Inhibiting glycosphingolipid synthesis improves glycemic control and insulin sensitivity in animal models of type 2 diabetes. Diabetes 56, 1210-1218 (2007).
31. McEachern, K.A. et al. A specifc and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Mol. Genet. Metab. 91, 259-267 (2007).
32. Lukina, E. et al. A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1. Blood published online, doi:10.1182/blood-2010-03-273151 (3 May 2010).
33. Smith, L.A. et al. Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities and common features with human disease. J. Am. Soc. Nephrol. 17, 2821-2831 (2006).
34. Takahashi, H. et al. A hereditary model of slowly progressive polycystic kidney disease in the mouse. J. Am. Soc. Nephrol. 1, 980-989 (1991).
35. Otto, E.A. et al. NEK8 mutations affect ciliary and centrosomal localization and may cause nephronophthisis. J. Am. Soc. Nephrol. 19, 587-592 (2008).
36. Natoli, T.A. et al. Pkd1 and Nek8 mutations affect cell-cell adhesion and cilia in cysts formed in kidney organ cultures. Am. J. Physiol. Renal Physiol. 294, F73-F83 (2008).
37. Shayman, J.A. et al. Modulation of renal epithelial cell growth by glucosylceramide. Association with protein kinase C, sphingosine, and diacylglycerol. J. Biol. Chem. 266, 22968-22974 (1991).
38. Seibler, J. et al. Rapid generation of inducible mouse mutants. Nucleic Acids Res. 31, e12 (2003).
39. Folch, J., Lees, M. & Sloane Stanley, G.H. A simple method for the isolation and purifcation of total lipides from animal tissues. J. Biol. Chem. 226, 497-509 (1957).
40. Jankowski, K. Microdetermination of phosphorus in organic materials from polymer industry by microwave-induced plasma atomic emission spectrometry after microwave digestion. Microchem. J. 70, 41-49 (2001). (Pubitemid 32778548)